慢性肝疾患に対する局所水素捕捉・触媒的水素化戦略による抗炎症効果の増強
Chronic liver disease (CLD), encompassing steatosis, inflammation, and fibrosis, is a major driver of cirrhosis and hepatocellular carcinoma. This study proposes a dual-function strategy in which palladium hydride (PdH) nanoparticles, administered intravenously, accumulate selectively in the liver and serve both as a hydrogen reservoir and a hydroxyl radical (·OH) scavenger. In a non-alcoholic steatohepatitis (NASH) mouse model, daily 4% H2 gas inhalation for 3 hours was combined with PdH nanoparticle preloading. Liver-targeted Pd nanoparticles captured circulating H2 and catalytically converted ·OH into water. This approach produced broad bioactivity encompassing lipid metabolism regulation and anti-inflammatory effects, substantially improving NASH outcomes. Following the experimental period, intramuscular glutathione (GSH) injection facilitated Pd clearance from the body. The findings demonstrate that combining PdH nanoparticles with H2 inhalation amplifies hepatic hydrogen bioavailability and enhances antioxidant efficacy beyond what either intervention achieves alone.
Intravenously administered Pd nanoparticles accumulate in hepatic tissue, where they capture and store inhaled H2 while catalytically reducing hydroxyl radicals (·OH) to water, thereby attenuating oxidative stress and inflammatory signaling in the liver.
This study combines multiple delivery routes. As a general principle, the most efficient route for routine hydrogen intake is inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/37215568